Table 1.
Patient demographics and characteristics (safety population)
| Parameter | Anagrelide (n = 76) | Hydroxyurea (n = 70) | Total (n = 146) |
|---|---|---|---|
| Age (years) | |||
| Mean (SD) | 52.1 (16.10) | 52.9 (15.80) | 52.5 (15.91) |
| Median (range) | 53.0 (18–78) | 57.0 (22–84) | 55.0 (18–84) |
| Age category (years), n (%) | |||
| 18– < 40 | 20 (26.3) | 16 (22.9) | 36 (24.7) |
| 40– < 60 | 21 (27.6) | 23 (32.9) | 44 (30.1) |
| 60– < 75 | 31 (40.8) | 28 (40.0) | 59 (40.4) |
| ≥ 75 | 4 (5.3) | 3 (4.3) | 7 (4.8) |
| Gender, n (%) | |||
| Female | 56 (73.7) | 45 (64.3) | 101 (69.2) |
| Race, n (%) | |||
| Caucasian | 75 (98.7) | 69 (98.6) | 144 (98.6) |
| Time since ET diagnosis (months) | |||
| Mean (SD) | 8.7 (13.65) | 14.6 (28.29) | 11.5 (22.04) |
| High-risk category fulfilled, n (%) | |||
| Platelet count ≥ 1000 × 109/L | 43 (56.6) | 50 (71.4) | 93 (63.7) |
| Age ≥ 60 years | 35 (46.1) | 32 (45.7) | 67 (45.9) |
| Previous history of thrombotic or haemorrhagic events | 12 (15.8) | 9 (12.9) | 21 (14.4) |
| Number of high-risk categories fulfilled, n (%) | |||
| 1 | 63 (82.9) | 50 (71.4) | 113 (77.4) |
| 2 | 12 (15.8) | 19 (27.1) | 31 (21.2) |
| 3 | 1 (1.3) | 1 (1.4) | 2 (1.4) |
| Bone marrow biopsy result—study centre result, n (%) | |||
| ET | 72 (94.7) | 68 (97.1) | 140 (95.9) |
| MPN, unclassifiable | 4 (5.3) | 2 (2.9) | 6 (4.1) |
| Bone marrow biopsy result (WHO classification)—central reading / final diagnosis, n (%) | |||
| ET | 41 (53.9) | 52 (74.3) | 93 (63.7) |
| Pre-PMF (fibrosis grade 0 or 1) | 10 (13.2) | 5 (7.1) | 15 (10.3) |
| Overt PMF (fibrosis grade 2) | 5 (6.6) | 4 (5.7) | 9 (6.2) |
| Polycythaemia vera | 3 (3.9) | 2 (2.9) | 5 (3.4) |
| MPN, unclassifiable | 5 (6.6) | 2 (2.9) | 7 (4.8) |
| Limited material/non-representative biopsy | 12 (157) | 5 (7.1) | 17 (11.6) |
| Prior use of platelet aggregation inhibitors, n (%) | 30 (39.5) | 22 (31.4) | 52 (35.6) |
ET essential thrombocythaemia; MPN myeloproliferative neoplasm; PMF primary myelofibrosis; SD standard deviation; WHO World Health Organization